Lead Product(s) : Ziresovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 3 AirFLO study with ziresovir, a novel small-molecule RSV fusion (F) protein inhibitor, met primary and key secondary endpoints of significant reduction of sign-and-symptom score (p=0.002) and viral load (p=0.006) respectively, compared with placeb...
Product Name : AK0529
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 04, 2022
Lead Product(s) : Ziresovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
